Gibbs Wealth Management’s West Pharmaceutical WST Stock Holding History

Gibbs Wealth Management’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$806K	Buy	3,216 +414	+15%	+$103K	0.11%	193
2025 Q4	$772K	Sell	2,802 -690	-20%	-$189K	0.19%	130
2025 Q3	$916K	Sell	3,492 -727	-17%	-$177K	0.21%	114
2025 Q2	$923K	Sell	4,219 -2,174	-34%	-$465K	0.18%	140
2025 Q1	$1.43M	Buy	6,393 +1,733	+37%	+$478K	0.35%	67
2024 Q4	$1.53M	Buy	4,660 +770	+20%	+$242K	0.41%	53
2024 Q3	$1.17M	Buy	3,890 +511	+15%	+$156K	0.38%	59
2024 Q2	$1.11M	Buy	3,379 +935	+38%	+$330K	0.45%	52
2024 Q1	$967K	Buy	+2,444	New	+$904K	0.56%	40

Other funds holding WST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Gibbs Wealth Management's WST Position: Q1 2026 in Review

Gibbs Wealth Management increased its West Pharmaceutical (WST) stake by 15% in Q1 2026, buying an estimated $103K and bringing the position to 3,216 shares worth $806K. The position accounts for 0.11% of the portfolio, ranked #193.

Gibbs Wealth Management first reported a position in WST in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.53M in Q4 2024. 755 funds tracked by Wall St. Rank hold WST as of Q1 2026.

Gibbs Wealth Management held 3,216 shares of West Pharmaceutical worth $806K as of Q1 2026.
Gibbs Wealth Management bought 414 West Pharmaceutical shares in Q1 2026, an estimated $103K.
West Pharmaceutical made up 0.11% of Gibbs Wealth Management's portfolio in Q1 2026, its #193 holding.
Gibbs Wealth Management first reported a position in West Pharmaceutical in Q1 2024 and has held it in 9 quarters since.
Gibbs Wealth Management's West Pharmaceutical position peaked at $1.53M in Q4 2024.
755 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.

Based on Gibbs Wealth Management's 13F filing for Q1 2026, filed 13 May 2026.